Enhabit, Inc. (NYSE:EHAB) Holdings Lifted by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Enhabit, Inc. (NYSE:EHAB) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 80,760 shares of the company’s stock after acquiring an additional 2,211 shares during the quarter. Rhumbline Advisers owned about 0.16% of Enhabit worth $631,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jane Street Group LLC raised its holdings in Enhabit by 514.3% during the 3rd quarter. Jane Street Group LLC now owns 901,084 shares of the company’s stock worth $7,119,000 after buying an additional 754,395 shares during the period. Systematic Financial Management LP raised its holdings in shares of Enhabit by 12.2% during the third quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock valued at $14,522,000 after acquiring an additional 199,235 shares during the period. Bardin Hill Management Partners LP lifted its position in shares of Enhabit by 927.4% in the 3rd quarter. Bardin Hill Management Partners LP now owns 174,304 shares of the company’s stock valued at $1,377,000 after acquiring an additional 157,338 shares in the last quarter. West Tower Group LLC lifted its position in shares of Enhabit by 108.8% in the 3rd quarter. West Tower Group LLC now owns 285,142 shares of the company’s stock valued at $2,253,000 after acquiring an additional 148,566 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Enhabit by 37.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 305,245 shares of the company’s stock worth $2,411,000 after purchasing an additional 83,707 shares during the period.

Enhabit Price Performance

Shares of EHAB stock opened at $8.53 on Friday. Enhabit, Inc. has a 52 week low of $6.85 and a 52 week high of $11.74. The stock has a market capitalization of $428.67 million, a PE ratio of -3.67 and a beta of 1.80. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The stock’s fifty day moving average is $8.18 and its 200-day moving average is $7.90.

Analysts Set New Price Targets

A number of research firms have issued reports on EHAB. Leerink Partners reiterated a “market perform” rating and issued a $8.00 target price (down previously from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and increased their price objective for the stock from $8.25 to $9.50 in a report on Monday, December 9th.

Insiders Place Their Bets

In related news, Director Stuart M. Mcguigan acquired 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of $8.81 per share, with a total value of $132,150.00. Following the transaction, the director now owns 46,810 shares of the company’s stock, valued at $412,396.10. The trade was a 47.15 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bolton bought 4,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the purchase, the director now directly owns 98,144 shares in the company, valued at approximately $852,871.36. This represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.90% of the company’s stock.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.